Development and Evaluation of a self-amplifying RNA vaccine against the S and N proteins of SARS-CoV-2
This project seeks to advance a thermostable RNA vaccine against COVID that would afford broad protection and will be manufactured in Cape Town, South Africa. The project comprises preclinical studies, complete toxicology studies for the lead candidate, and conduct a Phase 1 trial in healthy adult volunteers in Johannesburg.
Countries
Active Dates
03/01/2020 to 03/31/2024
Faculty Involved
Health Topics